According to filings with the U.S. Securities and Exchange Commission, Rejuvenate Bio is raising up to $27,049,354.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Rejuvenate Bio
Rejuvenate Bio is a biotechnology company developing novel, targeted gene therapies to treat aging and age-related diseases in humans and animals. At the core of its business, the company focuses on combination gene therapy and proprietary targets to address multiple chronic, age-related conditions simultaneously, aiming to improve healthspan and overall quality of life rather than tackling each disease in isolation. Originating from work in George Churchs lab at Harvard Medical School and the Wyss Institute, Rejuvenate Bio has advanced a pipeline that includes therapies shown to treat heart failure, kidney failure, diabetes, and obesity in mice, with programs that have progressed into dogs, including a leading therapy for canine heart failure. The company leverages the animal health market to bring anti-aging therapies to market in a capital-efficient way, while using the same preclinical data packages to support future human applications. Rejuvenate Bio has achieved notable milestones described on its site, including raising a Series A financing to further develop its age-reversal gene therapies and securing multiple grants from the U.S. Department of Defenses Special Operations Command, underscoring its emerging position as an innovator in the age-reversal and chronic disease space.

To learn more, visit https://rejuvenatebio.com/
LinkedIn: https://www.linkedin.com/company/rejuvenate-bio/

Contact:
John Park, General Counsel

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.